The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis

被引:0
|
作者
Fang, HuaLi [1 ]
Hou, YingDou [2 ]
Zhuang, Hui [3 ]
Wang, ChengHong [1 ]
机构
[1] Yantaishan Hosp, Dept Lab, Yantai 264000, Shandong, Peoples R China
[2] Weihai Stomatol Hosp, Dept Lab, Weihai City 264200, Shandong, Peoples R China
[3] Yantai City Ctr Blood Stn, Dept Lab, Yantai 264003, Shandong, Peoples R China
关键词
Psoriasis; Malassezia; Interleukin-23/Interleukin-17; axis; ANTIMICROBIAL PEPTIDES; CATHELICIDIN LL-37; EXPRESSION; IL-17;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We explore the association of Malassezia and IL-23/IL-17 axis in the skin lesions of patients with Psoriasis. From October 2018 to October 2020, 202 psoriasis patients were hospitalized in the dermatology department of Yantaishan hospital. The patients' skin lesions were collected, and Malassezia-specific mRNA in the skin lesions was determined. The patients were subdivided into Malassezia high and low distribution groups as per the Malassezia-specific mRNA results. Psoriasis Area and Severity Index (PASI) scores between the two groups were performed. LL-37, IL-23, IL-17A, and tumor necrosis factor alpha (TNF-alpha) expression in the skin lesions of the two groups were determined. Malassezia mRNA and the correlation of LL-37 with inflammatory factors TNF-alpha, IL-23, and IL-17A were determined. The relevance of inflammatory factors, Malassezia infection, and LL-37 content with PASI score were studied. The Malassezia high distribution group was treated with ketoconazole, and the effects of treatment on the PASI score, IL-23, TNF-alpha, and IL-17A were determined. The PASI score, neutrophil, eosinophil, and peripheral blood white blood cell counts, and lgG in the Malassezia high distribution group were significantly higher than in the low distribution group (P < 0.05). IL-23, LL-37, TNF-alpha, and IL-17A levels in the Malassezia high distribution group were significantly higher than in the low distribution group (P < 0.05). Malassezia and LL-37 levels had a moderate positive correlation (R=0.5009, P < 0.0001). Malassezia and LL-37, IL-17A, TNF-alpha, and IL-23 correlated positively. Malassezia, IL-17A, LL37, TNF-alpha, and IL-23 correlated positively with the PASI score of Psoriasis. Ketoconazole therapy inhibited the PASI score, IL-23, TNF-alpha, and IL-17A expressions in patients. Malassezia enhances the progression of Psoriasis through the aberrant activation of the IL-23/IL-17 axis.
引用
收藏
页码:130 / 137
页数:8
相关论文
共 50 条
  • [21] IL-23 and IL-17 in ankylosing spondylitis
    Daniel Wendling
    Rheumatology International, 2010, 30 : 1547 - 1547
  • [22] The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
    Brembilla, Nicolo Costantino
    Senra, Luisa
    Boehncke, Wolf-Henning
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [23] IL-17 targeted therapies for psoriasis
    Chiricozzi, Andrea
    Krueger, James G.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) : 993 - 1005
  • [24] Update on IL-17 Inhibitors for Psoriasis
    Levin A.A.
    Sobell J.M.
    Current Dermatology Reports, 2017, 6 (2) : 121 - 128
  • [25] Update on IL-17 Inhibitors for Psoriasis
    Singh, Rhea
    Balogh, Esther A.
    Feldman, Steven R.
    CURRENT DERMATOLOGY REPORTS, 2020, 9 (04) : 339 - 352
  • [26] Update on IL-17 Inhibitors for Psoriasis
    Rhea Singh
    Esther A. Balogh
    Steven R. Feldman
    Current Dermatology Reports, 2020, 9 : 339 - 352
  • [27] Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques
    Johnson-Huang, Leanne M.
    Suarez-Farinas, Mayte
    Sullivan-Whalen, Mary
    Gilleaudeau, Patricia
    Krueger, James G.
    Lowes, Michelle A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (11) : 2654 - 2663
  • [28] The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis
    Plachouri, K-M
    Chourdakis, V
    Georgiou, S.
    DRUGS OF TODAY, 2019, 55 (09) : 587 - 593
  • [29] Obesity and oxidative stress intensify psoriasis through activating IL-17/IL-23 pathway
    Vikasari, Suci Nar
    Sukandar, Elin Yulinah
    Suciati, Tri
    Adnyana, I. Ketut
    PHYSIOLOGY AND PHARMACOLOGY, 2024, 28 (01): : 18 - 26
  • [30] Targeting IL-17 with ixekizumab in patients with psoriasis
    Dyring-Andersen, Beatrice
    Skov, Lone
    Zachariae, Claus
    IMMUNOTHERAPY, 2015, 7 (09) : 957 - 966